

: US-10-578-672A-10
Perfect score: 397
Sequence: 1 gggccaggggatgatatgaa.....gtttccagagcctagcccct 397

RESULT 15

ABV95296/c

ID ABV95296 standard; cDNA; 449 BP.

XX

AC ABV95296;

XX

DT 14-JAN-2003 (first entry)

XX

DE Human pancreatic cancer expressed cDNA SEQ ID NO 704.

XX

KW Human; pancreas; cancer; gene therapy; vaccine; immunostimulant;

KW cytostatic; tumour; gene; ss.

XX

OS Homo sapiens.

XX

PN WO200260317-A2.

XX

PD 08-AUG-2002.

XX

PF 30-JAN-2002; 2002WO-US002781.

XX

PR 30-JAN-2001; 2001US-0265305P.

PR 31-JAN-2001; 2001US-0265682P.

PR 09-FEB-2001; 2001US-0267568P.

PR 21-MAR-2001; 2001US-0278651P.

PR 28-APR-2001; 2001US-0287112P.

PR 16-MAY-2001; 2001US-0291631P.

PR 12-JUL-2001; 2001US-0305484P.

PR 20-AUG-2001; 2001US-0313999P.

PR 27-NOV-2001; 2001US-0333626P.

XX

PA (CORI-) CORIXA CORP.

XX

PI Benson DR, Kalos MD, Lodes MJ, Persing DH, Hepler WT, Jiang Y;

XX

DR WPI; 2002-627435/67.

XX

PT New isolated polynucleotide and pancreatic tumor polypeptides, useful for

PT diagnosing, preventing and/or treating cancer, particularly pancreatic

PT cancer.

XX

PS Claim 1; SEQ ID NO 704; 300pp + Sequence Listing; English.

XX

CC The invention relates to an isolated polynucleotide (I) comprising: (a)

CC any of a group of over 4000 nucleotide sequences (ABV94628-ABV99145); (b)

CC complements of (a); (c) sequences consisting of at least 20 contiguous

CC residues of (a); (d) sequences that hybridize to (a), under moderately

CC stringent conditions; (e) sequences having at least 75% or 90% identity

CC to (a); or (f) degenerate variants of (a). Polypeptides (ABP68596-

CC ABP68637) encoded by (I) and oligonucleotide can be used to detect cancer

CC in a patient and compositions comprising polypeptides, polynucleotides,

CC antibodies, fusion proteins, T cell populations and antigen presenting

CC cells expressing the polypeptide are useful in treating pancreatic cancer

CC and stimulating an immune response. The polynucleotides can be used as

CC probes or primers for nucleic acid hybridisation, in the design and

CC preparation of ribozyme molecules for inhibiting expression of the tumour

CC polypeptides and proteins in the tumour cells, in vaccines and for gene

CC therapy. Note: The sequence data for this patent did not form part of the

CC printed specification, but was obtained in electronic format directly

CC from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 449 BP; 143 A; 91 C; 89 G; 125 T; 0 U; 1 Other;

Query Match 53.5%; Score 212.4; DB 6; Length 449;

Best Local Similarity 97.0%; Pred. No. 4.7e-38;

Matches 227; Conservative 0; Mismatches 6; Indels 1; Gaps 1;

```
Qy      2  GGCCAGGGGATGATATGAATGTCACAGGAGGAGACACCTTCTGTCTTTGTTTCAAAGAAA 61
      ||  ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      233 GGTGGGGGATGATATGAATGTCACAGGAGGAGACACCTTCTGTCTTTGTTTCAAAGAAA 174

Qy      62  GTTGATGTGCCATTGTGTTAATATACAAGAGAAATATTGAAAATATATTGAAAAGAGCAAT 121
      |  ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      173 G-TGATGTGCCATTGTGTTAATATACAAGAGAAATATTGAAAATATATTGAAAAGAGCAAT 115

Qy      122 TTTAAATTATTTTTGGCTTATGTTGCAATATTTATTTTCTTGTATTAGGAAAGATTCCTT 181
      ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      114 TTTAAATTATTTTTGGCTTATGTTGCAATATTTATTTTCTTGTATTAGAAAAGATTCCTT 55

Qy      182 TGTAGAAAAAAATGTATTTTCATTAACGCAAAAACCTATTTCTCCTTTTGT 235
      |||||  ||||||||||||||||||||||||||  ||||||||||||||||
Db      54  TGTAGAGAAAAAATGTATTTTCATTAACGCAAGACCTATTTCTCCTTTTGT 1
```